265 related articles for article (PubMed ID: 29272432)
1. Inhibition of antigen presentation during AAV gene therapy using virus peptides.
Shao W; Chen X; Samulski RJ; Hirsch ML; Li C
Hum Mol Genet; 2018 Feb; 27(4):601-613. PubMed ID: 29272432
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
3. Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model.
Kodippili K; Hakim CH; Pan X; Yang HT; Yue Y; Zhang Y; Shin JH; Yang NN; Duan D
Hum Gene Ther; 2018 Mar; 29(3):299-311. PubMed ID: 28793798
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
5. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy for muscular dystrophy].
Takeda S
No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
[TBL] [Abstract][Full Text] [Related]
7. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
Koo T; Popplewell L; Athanasopoulos T; Dickson G
Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
[TBL] [Abstract][Full Text] [Related]
8. Full-length dystrophin reconstitution with adeno-associated viral vectors.
Lostal W; Kodippili K; Yue Y; Duan D
Hum Gene Ther; 2014 Jun; 25(6):552-62. PubMed ID: 24580018
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice.
Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K
J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971
[TBL] [Abstract][Full Text] [Related]
10. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
[TBL] [Abstract][Full Text] [Related]
12. Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposure.
Radosevich TJ; Seregina T; Link CJ
Hum Gene Ther; 2003 Dec; 14(18):1765-75. PubMed ID: 14670127
[TBL] [Abstract][Full Text] [Related]
13. A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs.
Shin JH; Yue Y; Srivastava A; Smith B; Lai Y; Duan D
Hum Gene Ther; 2012 Feb; 23(2):202-9. PubMed ID: 21967249
[TBL] [Abstract][Full Text] [Related]
14. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
16. Genomic removal of a therapeutic mini-dystrophin gene from adult mice elicits a Duchenne muscular dystrophy-like phenotype.
Wasala NB; Lai Y; Shin JH; Zhao J; Yue Y; Duan D
Hum Mol Genet; 2016 Jul; 25(13):2633-2644. PubMed ID: 27106099
[TBL] [Abstract][Full Text] [Related]
17. Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes.
Berger C; Xuereb S; Johnson DC; Watanabe KS; Kiem HP; Greenberg PD; Riddell SR
J Virol; 2000 May; 74(10):4465-73. PubMed ID: 10775582
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model.
Wang B; Li J; Xiao X
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13714-9. PubMed ID: 11095710
[TBL] [Abstract][Full Text] [Related]
19. TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes.
Oosten LE; Koppers-Lalic D; Blokland E; Mulder A; Ressing ME; Mutis T; van Halteren AG; Wiertz EJ; Goulmy E
Int Immunol; 2007 Sep; 19(9):1115-22. PubMed ID: 17855435
[TBL] [Abstract][Full Text] [Related]
20. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.
Yue Y; Li Z; Harper SQ; Davisson RL; Chamberlain JS; Duan D
Circulation; 2003 Sep; 108(13):1626-32. PubMed ID: 12952841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
